Novartis AG
NVS
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $304.1B
$159.99
▼ -1.90%
P/E
24.06
Mkt Cap
$304.1B
52-Wk Range
$121.57–$170.46
52-Week Range
$121.57 - $170.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 23.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strong R&D pipeline with multiple late-stage drug candidates in high-value therapeutic areas
- Global manufacturing and distribution infrastructure with established market presence across developed and emerging markets
- Patent protection and intellectual property portfolio providing pricing power and market exclusivity for innovative medicines
- Diversified product portfolio reducing revenue concentration risk and providing stable cash flows
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Expansion of oncology and immunology franchises addressing growing cancer and autoimmune disease prevalence
Value
Fairly valued vs sector peers
Momentum
Strong
+7.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.86% yield
Smart-money signal
Who's buying NVS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 21, 2026
Reported EPS of $2.41 vs $2.17 consensus (+11.1% surprise). Revenue of $14.4B vs $14.1B expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.1%
Revenue trend · last 8Q
—
—
—
+15%
+9%
-2%
-1%
-3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$13.2B
$13.6B
$13.6B
$14.8B
$14.4B
$13.3B
$13.5B
$14.4B
Margins · last 8Q
Gross
74.5%
Operating
32.8%
Profit
22.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 22, 2026
vs Industry
How NVS stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.